Literature DB >> 16835373

Blockade of alpha v beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells.

Sylvie Maubant1, Dominique Saint-Dizier, Morgane Boutillon, Francoise Perron-Sierra, Patrick J Casara, John A Hickman, Gordon C Tucker, Ellen Van Obberghen-Schilling.   

Abstract

Alpha v integrins are thought to play an important role in tumor angiogenesis. However, discrepancies between findings with Arg-Gly-Asp (RGD) mimetics, which block angiogenesis in animal models, and knockout mice, in which loss of some alpha v integrins enhances tumor angiogenesis, raise questions concerning the function of these integrins and the precise role of alpha v substrate mimetics in antiangiogenic therapies. We have examined the effects of a novel non-peptide RGD mimetic, S 36578-2, on human endothelial cells to elucidate its antagonist activity and to identify possible agonist functions. S 36578-2 is highly selective for alpha v beta3 and alpha v beta5 integrins and induces detachment, caspase-8 activation, and apoptosis in human umbilical endothelial cells (HUVECs) plated on vitronectin. Importantly, the compound has no effect on the morphology or survival of cells plated on interstitial matrix components such as fibronectin, and it does not potentiate the apoptotic process in suspended cells. Identical results were obtained with a cyclic RGD peptide with similar target specificity. In microvascular endothelial cells, S 36578-2-induced death was also linked to its antiadhesive effect, with established lines markedly more resistant than primary cultures to the antiadhesive and proapoptotic effects. Altogether, these findings have important implications for the development of this class of antiangiogenics.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16835373     DOI: 10.1182/blood-2006-05-023580

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

1.  RGD-independent cell adhesion via a tissue transglutaminase-fibronectin matrix promotes fibronectin fibril deposition and requires syndecan-4/2 α5β1 integrin co-signaling.

Authors:  Zhuo Wang; Russell J Collighan; Stephane R Gross; Erik H J Danen; Gertraud Orend; Dilek Telci; Martin Griffin
Journal:  J Biol Chem       Date:  2010-10-07       Impact factor: 5.157

2.  A monoclonal antibody against alphaVbeta3 integrin inhibits development of atherosclerotic lesions in diabetic pigs.

Authors:  Laura A Maile; Walker H Busby; Timothy C Nichols; Dwight A Bellinger; Elizabeth P Merricks; Michael Rowland; Umadevi Veluvolu; David R Clemmons
Journal:  Sci Transl Med       Date:  2010-02-10       Impact factor: 17.956

3.  Combinatorial activation of FAK and AKT by transforming growth factor-beta1 confers an anoikis-resistant phenotype to myofibroblasts.

Authors:  Jeffrey C Horowitz; David S Rogers; Vishal Sharma; Ragini Vittal; Eric S White; Zongbin Cui; Victor J Thannickal
Journal:  Cell Signal       Date:  2006-11-17       Impact factor: 4.315

4.  Synthesis and activity of tumor-homing peptide iRGD and histone deacetylase inhibitor valproic acid conjugate.

Authors:  Zheng-Hong Peng; Jindřich Kopeček
Journal:  Bioorg Med Chem Lett       Date:  2014-03-12       Impact factor: 2.823

5.  An angiogenic inhibitor, cyclic RGDfV, attenuates MPTP-induced dopamine neuron toxicity.

Authors:  Aditiben Patel; Giuseppe V Toia; Kalea Colletta; Brinda Desai Bradaric; Paul M Carvey; Bill Hendey
Journal:  Exp Neurol       Date:  2011-06-15       Impact factor: 5.330

6.  Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism.

Authors:  Balveen Kaur; Sarah M Cork; Eric M Sandberg; Narra S Devi; Zhaobin Zhang; Philip A Klenotic; Maria Febbraio; Hyunsuk Shim; Hui Mao; Carol Tucker-Burden; Roy L Silverstein; Daniel J Brat; Jeffrey J Olson; Erwin G Van Meir
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

Review 7.  Integrins: masters and slaves of endocytic transport.

Authors:  Patrick T Caswell; Suryakiran Vadrevu; Jim C Norman
Journal:  Nat Rev Mol Cell Biol       Date:  2009-12       Impact factor: 94.444

8.  Intracellular targets of RGDS peptide in melanoma cells.

Authors:  Maria Simona Aguzzi; Paola Fortugno; Claudia Giampietri; Gianluca Ragone; Maurizio C Capogrossi; Antonio Facchiano
Journal:  Mol Cancer       Date:  2010-04-22       Impact factor: 27.401

9.  Mesenchymal migration as a therapeutic target in glioblastoma.

Authors:  Jessie Zhong; Andre Paul; Stewart J Kellie; Geraldine M O'Neill
Journal:  J Oncol       Date:  2010-06-21       Impact factor: 4.375

10.  The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy.

Authors:  Xinjie Lu; Dong Lu; Mike Scully; Vijay Kakkar
Journal:  Perspect Medicin Chem       Date:  2008-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.